Progyny (PGNY) Competitors $21.45 +0.21 (+0.99%) Closing price 07/3/2025 01:23 PM EasternExtended Trading$21.16 -0.29 (-1.33%) As of 07/3/2025 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PGNY vs. GH, OPCH, RDNT, BTSG, SHC, CON, PRVA, SGRY, WGS, and VCYTShould you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Surgery Partners (SGRY), GeneDx (WGS), and Veracyte (VCYT). These companies are all part of the "healthcare" industry. Progyny vs. Its Competitors Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Concentra Group Holdings Parent Privia Health Group Surgery Partners GeneDx Veracyte Progyny (NASDAQ:PGNY) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Do analysts rate PGNY or GH? Progyny currently has a consensus target price of $23.45, indicating a potential upside of 9.35%. Guardant Health has a consensus target price of $53.76, indicating a potential upside of 6.99%. Given Progyny's higher probable upside, analysts plainly believe Progyny is more favorable than Guardant Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Progyny 0 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.42Guardant Health 0 Sell rating(s) 0 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, PGNY or GH? Progyny has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProgyny$1.17B1.58$54.34M$0.5737.63Guardant Health$739.02M8.42-$436.37M-$3.39-14.82 Does the media favor PGNY or GH? In the previous week, Guardant Health had 8 more articles in the media than Progyny. MarketBeat recorded 13 mentions for Guardant Health and 5 mentions for Progyny. Guardant Health's average media sentiment score of 0.72 beat Progyny's score of 0.29 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Guardant Health 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in PGNY or GH? 94.9% of Progyny shares are held by institutional investors. Comparatively, 92.6% of Guardant Health shares are held by institutional investors. 9.4% of Progyny shares are held by company insiders. Comparatively, 6.1% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, PGNY or GH? Progyny has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Is PGNY or GH more profitable? Progyny has a net margin of 4.33% compared to Guardant Health's net margin of -53.82%. Progyny's return on equity of 10.90% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets Progyny4.33% 10.90% 7.20% Guardant Health -53.82%N/A -26.77% SummaryProgyny beats Guardant Health on 10 of the 16 factors compared between the two stocks. Get Progyny News Delivered to You Automatically Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGNY vs. The Competition Export to ExcelMetricProgynyMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.84B$7.31B$5.50B$9.01BDividend YieldN/A2.77%5.38%4.10%P/E Ratio37.6327.9427.5020.29Price / Sales1.5828.20389.64112.83Price / Cash61.5522.0836.6357.47Price / Book4.326.698.075.68Net Income$54.34M$233.06M$3.17B$248.96M7 Day Performance-2.10%1.74%2.81%3.30%1 Month Performance0.70%3.97%3.69%5.20%1 Year Performance-24.10%35.84%35.40%21.37% Progyny Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGNYProgyny1.0998 of 5 stars$21.45+1.0%$23.45+9.3%-24.1%$1.84B$1.17B37.63310GHGuardant Health3.7751 of 5 stars$48.55-1.2%$53.76+10.7%+76.9%$6.01B$774.00M-14.322,021Insider TradeOPCHOption Care Health4.3798 of 5 stars$31.05-1.5%$35.50+14.3%+11.5%$5.08B$5.19B25.048,088Positive NewsRDNTRadNet3.7022 of 5 stars$54.87-0.7%$69.60+26.8%-5.2%$4.12B$1.83B-127.6011,021BTSGBrightSpring Health Services1.6502 of 5 stars$22.77+2.2%$24.90+9.4%+95.5%$4.00B$11.27B81.3235,000SHCSotera Health2.9934 of 5 stars$11.09-2.6%$15.80+42.5%+0.8%$3.15B$1.10B138.643,000CONConcentra Group Holdings Parent3.3838 of 5 stars$20.95+1.0%$28.50+36.0%N/A$2.69B$1.90B15.6311,250Positive NewsPRVAPrivia Health Group4.1483 of 5 stars$21.61-1.1%$27.77+28.5%+30.4%$2.63B$1.74B180.101,140SGRYSurgery Partners2.6387 of 5 stars$20.20+4.7%$33.56+66.1%-6.1%$2.59B$3.11B-13.2015,000WGSGeneDx2.237 of 5 stars$79.71+19.0%$86.75+8.8%+227.2%$2.27B$305.45M-56.531,200Insider TradeHigh Trading VolumeVCYTVeracyte3.7682 of 5 stars$26.71+1.2%$40.90+53.1%+28.1%$2.09B$445.76M65.15790 Related Companies and Tools Related Companies Guardant Health Alternatives Option Care Health Alternatives RadNet Alternatives BrightSpring Health Services Alternatives Sotera Health Alternatives Concentra Group Holdings Parent Alternatives Privia Health Group Alternatives Surgery Partners Alternatives GeneDx Alternatives Veracyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGNY) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PGNY Stock Alerts